Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Other (2018 - 2025)

Historic Receivables - Other for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $19658.0.

  • China SXT Pharmaceuticals' Receivables - Other rose 11636.5% to $19658.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $19658.0, marking a year-over-year increase of 11636.5%. This contributed to the annual value of $417563.0 for FY2025, which is 39927.42% up from last year.
  • As of Q3 2025, China SXT Pharmaceuticals' Receivables - Other stood at $19658.0, which was up 11636.5% from $417563.0 recorded in Q1 2025.
  • China SXT Pharmaceuticals' Receivables - Other's 5-year high stood at $3.0 million during Q3 2021, with a 5-year trough of -$120122.0 in Q3 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' median Receivables - Other value was $230642.0 (recorded in 2023), while the average stood at $790443.8.
  • In the last 5 years, China SXT Pharmaceuticals' Receivables - Other surged by 54285.4% in 2021 and then crashed by 6373.86% in 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Receivables - Other (Quarter) stood at $3.0 million in 2021, then fell by 7.72% to $2.7 million in 2022, then crashed by 91.61% to $230642.0 in 2023, then plummeted by 152.08% to -$120122.0 in 2024, then skyrocketed by 116.37% to $19658.0 in 2025.
  • Its Receivables - Other stands at $19658.0 for Q3 2025, versus $417563.0 for Q1 2025 and -$120122.0 for Q3 2024.